Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Current Leases (2017 - 2023)

Aclaris Therapeutics has reported Current Leases over the past 5 years, most recently at $426000.0 for Q4 2023.

  • Quarterly results put Current Leases at $426000.0 for Q4 2023, down 37.72% from a year ago — trailing twelve months through Dec 2023 was $426000.0 (down 37.72% YoY), and the annual figure for FY2023 was $426000.0, down 37.72%.
  • Current Leases for Q4 2023 was $426000.0 at Aclaris Therapeutics, up from $310000.0 in the prior quarter.
  • Over the last five years, Current Leases for ACRS hit a ceiling of $766000.0 in Q3 2022 and a floor of $310000.0 in Q3 2023.
  • Median Current Leases over the past 3 years was $643500.0 (2022), compared with a mean of $585125.0.
  • Biggest five-year swings in Current Leases: dropped 1.3% in 2022 and later crashed 59.53% in 2023.
  • Aclaris Therapeutics' Current Leases stood at $693000.0 in 2021, then dropped by 1.3% to $684000.0 in 2022, then crashed by 37.72% to $426000.0 in 2023.
  • The last three reported values for Current Leases were $426000.0 (Q4 2023), $310000.0 (Q3 2023), and $458000.0 (Q2 2023) per Business Quant data.